Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Lieb

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|August 12, 2010
[Pharmacological neuroenhancement and brain doping : Chances and risks]A G Franke, K Lieb
Der Nervenarzt|May 27, 2018
[Resilience]K Lieb, A M Kunzler
Pharmacopsychiatry|October 9, 2004
Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorderA Philipsen, C Schmahl, K Lieb
Experimental Brain Research|January 1, 1994
Differentiation of hypothalamic GABAergic neurons in vitro: absence of effects of sex and gonadal steroidsK Lieb, I Reisert, C Pilgrim
Fortschritte Der Neurologie-Psychiatrie|June 9, 2009
[From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]A G Franke, K Lieb, A Fellgiebel
Pharmacopsychiatry|August 24, 2001
Inhibition of substance P-induced cytokine synthesis by St. John's wort extractsB L Fiebich, A Höllig, K Lieb
Current Medicinal Chemistry|February 28, 2002
Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugsM Hüll, K Lieb, B L Fiebich
Expert Opinion on Investigational Drugs|November 4, 2000
Anti-inflammatory drugs: a hope for Alzheimer's disease?M Hüll, K Lieb, B L Fiebich
Der Nervenarzt|October 24, 2000
[Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?]K Lieb, B L Fiebich, M Berger
Der Nervenarzt|December 31, 1997
[Systemic immunologic diseases as differential diagnosis in psychiatry]K Lieb, P Vaith, M Berger, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|August 12, 2010
[Pharmacological neuroenhancement and brain doping : Chances and risks]A G Franke, K Lieb
Der Nervenarzt|May 27, 2018
[Resilience]K Lieb, A M Kunzler
Pharmacopsychiatry|October 9, 2004
Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorderA Philipsen, C Schmahl, K Lieb
Experimental Brain Research|January 1, 1994
Differentiation of hypothalamic GABAergic neurons in vitro: absence of effects of sex and gonadal steroidsK Lieb, I Reisert, C Pilgrim
Fortschritte Der Neurologie-Psychiatrie|June 9, 2009
[From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]A G Franke, K Lieb, A Fellgiebel
Pharmacopsychiatry|August 24, 2001
Inhibition of substance P-induced cytokine synthesis by St. John's wort extractsB L Fiebich, A Höllig, K Lieb
Current Medicinal Chemistry|February 28, 2002
Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugsM Hüll, K Lieb, B L Fiebich
Expert Opinion on Investigational Drugs|November 4, 2000
Anti-inflammatory drugs: a hope for Alzheimer's disease?M Hüll, K Lieb, B L Fiebich
Der Nervenarzt|October 24, 2000
[Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?]K Lieb, B L Fiebich, M Berger
Der Nervenarzt|December 31, 1997
[Systemic immunologic diseases as differential diagnosis in psychiatry]K Lieb, P Vaith, M Berger, et al.
Pageof 10